Lowering Drug Prices by Once Again Putting Americans First

What it means

This order aims to lower prescription drug prices by improving upon existing programs, including the Medicare Drug Price Negotiation Program. It directs HHS to develop better drug pricing models, enhance transparency, and increase competition through measures like streamlined drug importation and reduced "middleman" costs.

Expected impact

• Potential savings for Medicare beneficiaries and patients through improved drug price negotiation and imported medications
• Enhanced competition in the pharmaceutical market through faster approval of generics and biosimilars
• More transparent pricing by requiring pharmacy benefit managers to disclose compensation
• Increased access to affordable insulin and epinephrine for low-income individuals
• Possible resistance from pharmaceutical manufacturers and industry stakeholders